Search

Displaying results 7561 - 7570 of 10000 in total
  1. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    Androstenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. … to a 3-keto group (3-hydroxysteroid dehydrogenases).

  2. Drug

    GSK-1004723

    go.drugbank.com/drugs/DB12806
    Investigational

    Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.

  3. Drug

    Corticorelin acetate

    go.drugbank.com/drugs/DB12915
    Investigational

    Corticorelin acetate has been investigated for the treatment of Brain Edema and Brain Tumor.

  4. Drug

    Nepicastat

    go.drugbank.com/drugs/DB12979
    Investigational

    Nepicastat has been investigated for the treatment of Cocaine Dependence and Posttraumatic Stress Disorder.

  5. Drug

    Rhodamine B

    go.drugbank.com/drugs/DB16853
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    WP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

    Synonyms: 3,6-di-O-acetyl-2-deoxy-D-glucopyranose, an acetic acid diester of 2-deoxy-D-glucose
  7. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication … R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors.

  8. Drug

    Benorilate

    go.drugbank.com/drugs/DB13657
    Approved

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  9. Drug

    Ulixertinib

    go.drugbank.com/drugs/DB13930
    Investigational

    It is currently in clinical trials for the treatment of a wide range of tumors. … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity [A31474].

  10. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to